Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma ; volume:10 ; number:1 ; year:2019 ; pages:67-74
Case reports in ophthalmology ; 10, Heft 1 (2019), 67-74
- Creator
-
Obata, Shumpei
Saishin, Yoshitsugu
Teramura, Kazuya
Ohji, Masahito
- DOI
-
10.1159/000496682
- URN
-
urn:nbn:de:101:1-2019051601092910302747
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Obata, Shumpei
- Saishin, Yoshitsugu
- Teramura, Kazuya
- Ohji, Masahito
Other Objects (12)
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Dormancy of cutaneous melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cutaneous melanoma in older patients
Bilateral uveitis and macular edema induced by Nivolumab: a case report
Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma
Hidden Sentinel Node in Cutaneous Melanoma
Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies
Management of Localized Melanoma in the Anti-PD-1 Era
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Dormancy of cutaneous melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cutaneous melanoma in older patients
Bilateral uveitis and macular edema induced by Nivolumab: a case report
Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma
Hidden Sentinel Node in Cutaneous Melanoma
Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies
Management of Localized Melanoma in the Anti-PD-1 Era
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Dormancy of cutaneous melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Cutaneous melanoma in older patients
Bilateral uveitis and macular edema induced by Nivolumab: a case report
Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
Bilateral Vitiligo-Like Depigmentation of Choroid and Retinal Pigment Epithelium Associated with Ipilimumab-Nivolumab Therapy for Metastatic Cutaneous Melanoma
Hidden Sentinel Node in Cutaneous Melanoma
Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies
Management of Localized Melanoma in the Anti-PD-1 Era